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burden was 48.2%, 45.3% and 39.2%. CONCLUSIONS: The study suggests the 
economic burden of osteoporosis fractures is substantial in terms of LOS and 
inpatient costs and elderly fracture patients consume significantly more 
resources. Patient co-pay rates decreased due to an increase in the 
reimbursement rates from health care. The rising trend in osteoporosis fractures 
may pose a huge burden to China.  
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OBJECTIVES: Rheumatoid arthritis (RA), an autoimmune condition, and 
osteoarthritis (OA), a degenerative joint disorder, are both associated with 
inflammatory reactions. Pain relievers could ameliorate this economic burden; 
however depending on the first-line treatment chosen they could raise the 
likelihood of gastrointestinal (GI) complications or cardiovascular (CV) events. 
The aim of this study is to calculate the direct and indirect costs of GI and CV 
events associated with common pain relievers for RA and OA patients in Brazil, 
Mexico, Colombia, Argentina and Costa Rica from the public payer’s perspective. 
METHODS: Resource use and medical cost data was collected in 2011 from local 
official databases and public hospital records from each noted LA market (all 
costs are expressed in 2012 US$). Events considered in this assessment were: 
dyspepsia, symptomatic ulcer, major bleedings (severe GI complication), 
myocardial infarction, ischemic stroke and heart failure. Direct medical costs 
considered were: outpatient visits, inpatient costs, lab and diagnostic tests, 
acquisition drug costs, concomitant medication, and emergency room services. 
To estimate indirect costs, human capital approach was considered involving 
productivity losses based in average wages for each LA market. RESULTS: Among 
LA countries, Brazil showed the highest overall adverse event cost per patient 
with dyspepsia (US$97.10) and Costa Rica the lowest (US$57.00). In addition, a 
symptomatic ulcer cost ranged between US$933.00 - US$705.60; major bleeding 
(US$6,807.30 - US$4,960.40); myocardial infarction (US$13,330.30 - US$7916.70); 
ischemic stroke (US$6,427.20 - US$3125.00) and heart failure (US$7,221.70 - 
US$4,152.80). In average, Brazilian and Mexican overall costs were among the 
highest, as opposed to Argentina and Costa Rica which were among the 
countries with lowest costs. Indirect costs followed the same trend (less than 
15% of total direct costs). CONCLUSIONS: Unexpected event costs associated 
with pain relievers could raise the economic burden of OA and RA significantly 
in LA. Thus, these findings could help decision makers to identify cost-effective 
pain therapies in markets where this cost data is unavailable.  
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OBJECTIVES: Osteoarthritis (OA) and rheumatoid arthritis (RA) are conditions 
that are associated with significant clinical burden and impact patients’ 
functional status and quality of life. Medical costs related to treating these 
common and disabling conditions place an economic strain on health care 
systems. The aim of this assessment is to compare celecoxib against 
nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) plus proton 
pump inhibitors (PPI) in five Latin American markets from the public payer’s 
perspective. METHODS: A cost-effectiveness evaluation was performed using a 
Markov modeling approach within a five-year time horizon (twelve-week cycles). 
The model compares celecoxib (200mg bid) against nsNSAIDs (naproxen 
500mg/bid; diclofenac 100mg/bid) alone and combined with PPI (omeprazole 
20mg/day). Model results were subdivided into two risk subpopulations: a) 
patients at low risk of GI and CV events (age 55+ with no prior risk factors); b) 
patients at high risk (age 65+ with previous risk factors). Efficacy and safety were 
retrieved from clinical literature (CONDOR Trial) and model uses Quality-
Adjusted Life Years Gained (QALYs) as effectiveness measurement. Resource use 
and medical cost data was collected from local official databases and public 
hospital records from each LA market (expressed in 2012 US$). Costs and 
consequences were discounted at 5% annually and probabilistic sensitivity 
analyses (PSA) were conducted. RESULTS: Celecoxib showed the highest health 
benefits (4.488 QALYs) compared to diclofenac (4.308 QALYs, +PPI 4.392 QALYs) 
and naproxen (4.241 QALYs, +PPI 4.355 QALYs). Regarding medical costs, in Brazil 
and Mexico celecoxib showed to be a cost-saving strategy within the high risk 
subpopulation. In other LA markets, celecoxib resulted as a cost-effective option 
with an average ICER of US$11,239.50 and US$8,046.20 in low and high risk 
subpopulations, respectively. PSA support robustness of the results. 
CONCLUSIONS: Despite higher acquisition cost compared to nsNSAIDs, celecoxib 
was found to be a cost-effective therapy for patients with OA and RA in multiple 
LA health care systems.  
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OBJECTIVES: Osteoporotic Fractures (OF) in elderly people are common 
worldwide, and the predicted aging of populations is increasing the burden of OF 
on health care systems. This study estimates the economic burden of OF in aged 
65 years and over in South Korea from a societal perspective. METHODS: 
National health insurance claim databases were used to analyze annual health 
care utilization and medical costs of OF in the South Korean population (49.78 
million). We identified medical claims records for elderly people with a diagnosis 
of OF and estimated the costs by a macro-costing method from 2007 to 2011. 
RESULTS: From 2007 to 2011, there were 244,798 elderly patients with at least 1 
medical insurance claim related to OF. Most patients had a single fracture (83%), 
while 17% of all patients had two or more. By fracture site, vertebral fracture 
accounted for 76.3% of all fractures, followed by 9.9% for hip fracture and 7.5% 
for wrist fracture. The societal cost of OF increased annually, from $83.7 million 
in 2007 to $141.4 million in 2011. For the societal cost of OF, direct medical cost 
was $134.9 million in 2011, which includes cost of treatment ($88.3 million) and 
long-term care ($46.6 million). The direct non-medical cost (transportation and 
caregiver costs) was estimated at $6.5 million in 2011. Costs associated with 
morbidity and mortality of OF were excluded due to the characteristics of the 
patients such as age, disability level and age at death. CONCLUSIONS: The 
results of this study indicate that the economic burden associated with OF in 
elderly people in Korea is considerable and is expected to rise with the predicted 
increases in life expectancy and the number of elderly in South Korea. Therefore, 
effective management of the disease is necessary to reduce the growth in the 
economic burden of OF.  
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OBJECTIVES: To describe drug use, drug switch and cost evaluation in patients 
with rheumatoid arthritis (RA). METHODS: Data derived from ARNO Observatory, 
an Italian population-based patient-centric system through record linkage of 11 
million inhabitants. In a sub-cohort of 5,821,337 people, we identified 15,082 
subjects with rheumatoid arthritis in 2011. Data were retrived for all these 
patients back to 2010 in order to esteem disease incidence. A cohort matched by 
sex, age and local health unit was computed to estimate differences in health 
costs. RESULTS: Prevalence of RA was 0.26% with an average age of 62 years and 
a percentage of women of 77%. Incidence is about 0.03% per year. The cost per-
person is €2,823 per year, 128% more in comparison with pair-matched group. 
This cost is for €1,230 due to drugs (€564 specific drugs, €666 others), €1,024 due 
to hospitalization and €569 due to lab tests and diagnostic examinations. Most 
common drugs are methylprednisolone+prednisone (63% treated), methotrexate 
(47.2%) and hydroxychloroquine (31.6%). Biological drugs are used by 3% of 
patients, but this percentage is increasing by years. Patients treated with 
biological drugs cost three times higher than others. Patients usually start first 
treatment with methylprednisolone+prednisone (46.6%), 25.2% start with 
methylprednisolone+prednisone and other specific drugs and 12.1% with 
methotrexate. One year after the first treatment only 40.1% of patients continue 
receiving the same treatment, 41.4% add a specific drug, 11.7% leave therapy and 
6.8% switch to another specific drug. CONCLUSIONS: This administrative 
database is an important source of information that is able to show both 
economical indicators and the good practice of treatment. In this study, they 
point out an elevated cost per-person in drugs assumption and show very 
current tendency to switch therapy in the first year.  
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OBJECTIVES: To identify factors associated with the cost of RA care and calculate 
risk-adjusted costs associated with RA in Turkey. We also examined the 
relationships between costs of RA treatment and global disease activity. 
METHODS: This cross-sectional study was performed in 10 university 
rheumatology centers. Eligible patients were ≥18 years of age and diagnosed with 
RA for at least 12 months according to the American College of Rheumatology 
(ACR) 1987 criteria. Generalized linear models were used to calculate risk-
adjusted direct costs. After using the Park test, the Gamma family with log link 
was chosen for the model. Age, gender, region, RA-related medication use and 
comorbidities such as diabetes, cardiovascular and respiratory disease, allergy 
and surgery were controlled in the model. Costs were adjusted by exchange rate 
of €1=2.30 Turkish Lira. RESULTS: A total of 698 patients (82% female; mean age: 
51.2±13.17 standard deviation [SD] years) were studied. Patients’ visual analog 
scale (VAS), patient’s global disease activity (GDA) and routine assessment of 
patient index data 3 (RAPID-3) scores were on average 44.15, 5.19 and 5.10 
respectively. Most patients were prescribed immunosuppressive medication and 
glucocorticoids (87.8% and 61.2%, respectively). Risk adjusted costs were 
estimated as €2,671. The most significant portion of overall expenditures was 
due to pharmaceutical costs €1987, while outpatient costs were €303, inpatient 
costs were €360 and co-payments were €21. 14% of patients experienced work 
loss due to RA. On average, annual costs due to workday loss were €480. 5.4% of 
patients also had other RA-related consultations, which were not covered by 
